Compare Stocks: EVGN, CARM, NCEL, and HOWL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARM Carisma Therapeutics	$0.00	$0.01	$0.00 ▼ $0.56	$105K	-9.09	68,411 shs	577 shs
EVGN Evogene	$0.70 +10.8%	$0.53	$0.37 ▼ $1.50	$5.51M	1.4	639,098 shs	348,422 shs
HOWL Werewolf Therapeutics	$0.38 +0.4%	$0.38	$0.27 ▼ $2.38	$18.57M	0.29	695,720 shs	146,099 shs
NCEL NLS Pharmaceutics	$3.19 -1.8%	$3.57	$1.83 ▼ $28.03	$17.37M	0.94	12,777 shs	17,802 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARM Carisma Therapeutics	0.00%	0.00%	-54.55%	+2,400.00%	-99.09%
EVGN Evogene	+10.79%	+7.77%	+36.82%	-7.83%	-42.11%
HOWL Werewolf Therapeutics	+0.45%	-7.45%	-4.79%	-34.29%	-67.48%
NCEL NLS Pharmaceutics	-1.85%	-7.54%	-23.87%	-1.54%	-84.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARM Carisma Therapeutics	$0.00	$0.01	$0.00 ▼ $0.56	$105K	-9.09	68,411 shs	577 shs
EVGN Evogene	$0.70 +10.8%	$0.53	$0.37 ▼ $1.50	$5.51M	1.4	639,098 shs	348,422 shs
HOWL Werewolf Therapeutics	$0.38 +0.4%	$0.38	$0.27 ▼ $2.38	$18.57M	0.29	695,720 shs	146,099 shs
NCEL NLS Pharmaceutics	$3.19 -1.8%	$3.57	$1.83 ▼ $28.03	$17.37M	0.94	12,777 shs	17,802 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARM Carisma Therapeutics	0.00%	0.00%	-54.55%	+2,400.00%	-99.09%
EVGN Evogene	+10.79%	+7.77%	+36.82%	-7.83%	-42.11%
HOWL Werewolf Therapeutics	+0.45%	-7.45%	-4.79%	-34.29%	-67.48%
NCEL NLS Pharmaceutics	-1.85%	-7.54%	-23.87%	-1.54%	-84.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CARM Carisma Therapeutics	1.00	Sell	N/A	N/A
EVGN Evogene	1.00	Sell	N/A	N/A
HOWL Werewolf Therapeutics	2.14	Hold	$3.75	877.33% Upside
NCEL NLS Pharmaceutics	2.00	Hold	$23.00	621.00% Upside

Current Analyst Ratings Breakdown

Latest EVGN, CARM, NCEL, and HOWL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/13/2026	NCEL NLS Pharmaceutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/13/2026	NCEL NLS Pharmaceutics	Laidlaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$23.00
7/8/2026	EVGN Evogene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/29/2026	NCEL NLS Pharmaceutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E)
6/16/2026	HOWL Werewolf Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CARM Carisma Therapeutics	$10.77M	0.01	N/A	N/A	($0.67) per share	0.00
EVGN Evogene	$3.85M	1.59	N/A	N/A	$1.37 per share	0.51
HOWL Werewolf Therapeutics	$1.88M	9.92	N/A	N/A	$0.34 per share	1.13
NCEL NLS Pharmaceutics	N/A	N/A	N/A	N/A	$1.59 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CARM Carisma Therapeutics	-$60.48M	$0.73	0.00	N/A	N/A	-254.28%	N/A	-192.17%	N/A
EVGN Evogene	-$8.48M	-$1.39	N/A	N/A	N/A	-638.12%	-158.82%	-80.37%	8/18/2026 (Estimated)
HOWL Werewolf Therapeutics	-$60.82M	-$0.76	N/A	N/A	N/A	N/A	-166.99%	-59.88%	8/13/2026 (Estimated)
NCEL NLS Pharmaceutics	-$8.30M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest EVGN, CARM, NCEL, and HOWL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	EVGN Evogene	-$0.27	N/A	N/A	N/A	$0.33 million	N/A
8/13/2026	Q2 2026	HOWL Werewolf Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
7/31/2026	Q2 2026	HOWL Werewolf Therapeutics	-$0.28	$0.08	+$0.36	$0.08	$21.00 million	$21.00 million
5/16/2026	Q1 2026	EVGN Evogene	-$0.27	-$0.60	-$0.33	-$0.60	$0.35 million	$0.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CARM Carisma Therapeutics	N/A	N/A	N/A	N/A	N/A
EVGN Evogene	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
NCEL NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CARM Carisma Therapeutics	N/A	0.48	0.48
EVGN Evogene	N/A	2.79	2.76
HOWL Werewolf Therapeutics	N/A	2.91	2.91
NCEL NLS Pharmaceutics	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CARM Carisma Therapeutics	44.27%
EVGN Evogene	10.40%
HOWL Werewolf Therapeutics	64.84%
NCEL NLS Pharmaceutics	N/A

Insider Ownership

Company	Insider Ownership
CARM Carisma Therapeutics	6.90%
EVGN Evogene	7.40%
HOWL Werewolf Therapeutics	23.60%
NCEL NLS Pharmaceutics	16.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CARM Carisma Therapeutics	20	41.85 million	38.91 million	No Data
EVGN Evogene	140	8.72 million	8.07 million	No Data
HOWL Werewolf Therapeutics	40	48.60 million	37.13 million	Optionable
NCEL NLS Pharmaceutics	6	5.35 million	4.47 million	Not Optionable

EVGN, CARM, NCEL, and HOWL Headlines

Recent News About These Companies

NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing

July 31, 2026 | globenewswire.com

NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board

July 8, 2026 | globenewswire.com

NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

July 1, 2026 | globenewswire.com

NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform

June 15, 2026 | globenewswire.com

NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes

May 27, 2026 | globenewswire.com

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

April 30, 2026 | globenewswire.com

Michel Revel Purchases 54,545 Shares of NLS Pharmaceutics (NASDAQ:NCEL) Stock

April 30, 2026 | insidertrades.com

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

April 20, 2026 | globenewswire.com

NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing

April 1, 2026 | globenewswire.com

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

March 9, 2026 | prnewswire.com

NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy

February 12, 2026 | prnewswire.com

NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences

January 29, 2026 | prnewswire.com

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression

January 12, 2026 | prnewswire.com

NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

January 5, 2026 | prnewswire.com

NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China

December 11, 2025 | prnewswire.com

NewCelX Appoints EY as New Auditor Following Merger

November 20, 2025 | tipranks.com

NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

November 17, 2025 | prnewswire.com

NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board

November 6, 2025 | prnewswire.com

NewcelX Ltd.

November 5, 2025 | cnn.com

NewcelX Ltd.: NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.

November 4, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN, CARM, NCEL, and HOWL Company Descriptions

Carisma Therapeutics NASDAQ:CARM

$0.0025 0.00 (0.00%)

As of 08/11/2026 10:29 AM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Evogene NASDAQ:EVGN

$0.70 +0.07 (+10.79%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$0.68 -0.02 (-2.21%)

As of 09:04 AM Eastern

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Werewolf Therapeutics NASDAQ:HOWL

$0.38 +0.00 (+0.45%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$0.39 +0.00 (+0.86%)

As of 08:58 AM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

NLS Pharmaceutics NASDAQ:NCEL

$3.19 -0.06 (-1.85%)

As of 08/11/2026 03:59 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVGN, CARM, NCEL, and HOWL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVGN, CARM, NCEL, and HOWL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVGN, CARM, NCEL, and HOWL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN, CARM, NCEL, and HOWL Company Descriptions

Carisma Therapeutics NASDAQ:CARM

Evogene NASDAQ:EVGN

Werewolf Therapeutics NASDAQ:HOWL

NLS Pharmaceutics NASDAQ:NCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVGN, CARM, NCEL, and HOWL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVGN, CARM, NCEL, and HOWL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVGN, CARM, NCEL, and HOWL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN, CARM, NCEL, and HOWL Company Descriptions

Carisma Therapeutics NASDAQ:CARM

Evogene NASDAQ:EVGN

Werewolf Therapeutics NASDAQ:HOWL

NLS Pharmaceutics NASDAQ:NCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools